Retatrutide Phase 3 Obesity Trial NCT05929066 Marked Completed

On August 21, 2026, the clinical trial registry updated the status of a retatrutide study to completed. The trial, titled "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight," is registered under identifier NCT05929066. It is listed as a Phase 3 study. The registry entry reflects only a change in trial status and does not include results data in this update. No outcome measures, efficacy findings, or safety conclusions were provided alongside this status change. The completion designation indicates that the trial has reached its concluding stage according to the registry record. Readers should note that a status of completed refers to the trial's operational timeline and does not by itself confirm what results, if any, will be published. Further details, including any results or subsequent publications, would need to be reported separately once made available. This brief reflects the information contained in the registry update as of the stated date. For additional context on retatrutide, including its regulatory status and background, readers can consult the compound overview.